Latest / Seattle News Today | 2 Min News | The Daily News Now!
Baricitinib Trial Targets Long COVID Symptoms | Seattle News
Big news for Long COVID sufferers: Providence Swedish is now enrolling patients in the federally funded REVERSE-LC trial, testing Baricitinib—a drug already approved for COVID and rheumatoid arthritis—to tackle persistent brain fog, memory loss, and crushing fatigue. This randomized, double-blind study targets adults with symptoms lasting at least six months post-infection, and Providence Swedish is the only Pacific Northwest site participating. With 550 participants nationwide, this could be a major step toward treating Long COVID’s lingering effects. Listen in comfort:Get a discount on a…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.